Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
BERKELEY, Calif., Dec. 02, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at Oppenheimer’s 26th Annual Healthcare Conference in New York on Wednesday, December 9, 2015, at 9:45 am Eastern Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is a clinical-stage immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 [email protected]
